UPDATE: Sarepta Announces Positive Safety Results from Phase I Trial of Marburg Drug Candidate

Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers. AVI-7288, which uses Sarepta's advanced and proprietary PMOplus™ chemistry, is the company's lead drug candidate for the treatment of Marburg virus infection. Sarepta